Sanofi India rose 3.58% to Rs 7,252 after standalone net profit jumped 22.69% to Rs 97.30 crore in Q4 December 2019 (Q4FY19) as against Rs 79.30 crore reported in Q4 December 2018 (Q4FY18).
Revenue from operations soared 13.75% year-on-year (Y-o-Y) to Rs 826.30 crore in Q4FY19. The Q4 figures were announced after market hours yesterday, 25 February 2020.
Profit before tax surged 23.31% to Rs 161.30 crore Y-o-Y. Current tax expenses rose by 29.05% to Rs 72.40 crore during the period under review.
Net profit rose 8.82% to Rs 414.20 crore on a 10.81% jump in revenue from operations to Rs 3,070.60 crore in the year ended December 2019 over the year ended December 2018.
Sanofi India has recommended a dividend of Rs 106 per equity share of Rs 10 for the year ended 31 December 2019. In addition, after reviewing the cash requirements for the firm's operations, a one-time special dividend of Rs 243 per equity share of Rs 10 is being recommended. The total dividend of Rs 349 per equity share of Rs 10 will be paid after approval of shareholders at the ensuing Annual General Meeting (AGM) of the company.
Also Read
On BSE, 6838 shares were traded in Sanofi India counter, compared to a 2-week average of 1447 shares. The stock hit an intraday high of Rs 7637.55, which is also an all-time record high for the counter. It hit an intraday low of Rs 7,160.45. It hit a 52-week low of Rs 5,300 on 24 June 2019.
Sanofi India is engaged in the manufacture and sale of pharmaceutical products. It provides medicines for the treatment of patients in various therapeutic areas, including cardiology, thrombosis, oncology, diabetes, central nervous system, internal medicine and consumer healthcare.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
